Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Statement of Comprehensive Income
- Analysis of Profitability Ratios
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Dividend Discount Model (DDM)
- Current Ratio since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
The operational efficiency of the entity is characterized by relatively stable collection and payment cycles, though inventory management and working capital turnover exhibit notable volatility. The overall trend indicates a period of consistent performance followed by a marked increase in the duration of the operating and cash conversion cycles in the final reporting period.
- Inventory and Operating Cycle Analysis
- Inventory turnover remained largely consistent between 3.5 and 4.1 for the majority of the period, with the average inventory processing period generally fluctuating between 88 and 104 days. A significant deviation occurred in the final quarter, where the processing period extended to 114 days, contributing to a peak operating cycle of 172 days. This indicates a recent deceleration in the movement of goods from procurement to sale.
- Receivables and Payables Management
- The receivable collection period demonstrated high stability, maintaining a tight range between 51 and 60 days throughout the entire observed timeframe. Similarly, the average payables payment period remained consistent, typically fluctuating between 60 and 73 days. The stability of these two metrics suggests a disciplined approach to credit management and a steady relationship with suppliers.
- Working Capital and Cash Conversion
- Working capital turnover experienced extreme volatility, reaching a low of 2.18 in September 2023 before spiking to a peak of 8.85 by December 2024. This suggests significant shifts in the utilization of current assets and liabilities relative to revenue. The cash conversion cycle reflects these fluctuations, remaining mostly between 75 and 98 days, but ending with a sharp increase to 108 days in the final period, primarily driven by the aforementioned increase in inventory processing time.
Turnover Ratios
Average No. Days
Inventory Turnover
| Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Cost of sales | ||||||||||||||||||||||||
| Inventories | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Inventory turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q2 2026 Calculation
Inventory turnover
= (Cost of salesQ2 2026
+ Cost of salesQ1 2026
+ Cost of salesQ4 2025
+ Cost of salesQ3 2025)
÷ Inventories
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of inventory turnover reveals a period of relative stability followed by significant volatility in the most recent quarters. The turnover ratio generally fluctuated between 3.50 and 4.00 for the majority of the observed timeframe, indicating a consistent pace of inventory movement relative to the cost of sales before experiencing a notable decline in the final period.
- Inventory Turnover Efficiency
- The turnover ratio reached a peak of 4.15 in December 2024, marking the highest level of inventory utilization efficiency within the analyzed timeframe. Following this peak, the ratio exhibited a downward trajectory, culminating in a period low of 3.20 by June 2026. This decline suggests a slowing of inventory liquidation relative to the cost of goods sold.
- Inventory Level Dynamics
- A general downward trend in inventory holdings was observed from April 2022 through December 2024, with levels dropping from 3.07 billion USD to a low of 2.33 billion USD. This reduction in stock levels was a primary driver of the efficiency gains seen in late 2024. However, this trend reversed sharply in the final quarter of the data, with inventories surging to 3.26 billion USD by June 2026, the highest level recorded in the entire period.
- Cost of Sales and Ratio Correlation
- The cost of sales exhibited moderate fluctuations, ranging from a high of 3.43 billion USD in December 2022 to lows near 2.23 billion USD in December 2024. The efficiency spike in December 2024 was the result of the lowest recorded inventory levels coinciding with a stable cost of sales. Conversely, the significant drop in the turnover ratio in June 2026 is directly attributable to the rapid increase in inventory volume which outpaced the corresponding cost of sales of 2.65 billion USD.
Receivables Turnover
| Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Sales | ||||||||||||||||||||||||
| Trade accounts receivable, less allowance for doubtful accounts | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Receivables turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q2 2026 Calculation
Receivables turnover
= (SalesQ2 2026
+ SalesQ1 2026
+ SalesQ4 2025
+ SalesQ3 2025)
÷ Trade accounts receivable, less allowance for doubtful accounts
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of receivables turnover from April 2022 through June 2026 reveals a period of fluctuation in collection efficiency aligned with shifts in quarterly sales volume and total outstanding receivables.
- Revenue and Receivables Correlation
- A notable transition occurred between the end of 2022 and early 2023. Sales reached a peak in December 2022 at US$ 8,369 million, which coincided with the highest reported trade receivables of US$ 4,918 million. Following this peak, both metrics entered a downward trajectory. By June 2024, trade receivables reached a minimum of US$ 3,298 million, reflecting a leaner balance sheet despite lower quarterly sales compared to the 2022 levels.
- Receivables Turnover Performance
- The turnover ratio exhibited volatility throughout the period, oscillating between a low of 6.09 in December 2023 and a peak of 7.15 in June 2024. The significant increase in efficiency during the first half of 2024 is attributed to a more rapid reduction in the receivables balance relative to the decline in sales. This indicates a temporary improvement in collection velocity or a strategic tightening of credit terms during that interval.
- Long-term Trend Analysis (2025-2026)
- From March 2025 through June 2026, the turnover ratio shows a gradual softening, declining from 6.79 to 6.33. This trend corresponds with a steady increase in trade accounts receivable, which rose from US$ 3,506 million in December 2024 to US$ 3,965 million by June 2026. Because the growth in sales during this period did not outpace the increase in outstanding receivables, a downward trend in the turnover ratio is observed, suggesting a possible lengthening of the average collection period.
Payables Turnover
| Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Cost of sales | ||||||||||||||||||||||||
| Trade accounts payable | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Payables turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Payables Turnover, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q2 2026 Calculation
Payables turnover
= (Cost of salesQ2 2026
+ Cost of salesQ1 2026
+ Cost of salesQ4 2025
+ Cost of salesQ3 2025)
÷ Trade accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of operating activity ratios indicates a general increase and subsequent stabilization in payables turnover over the observed period. The ratio progressed from a baseline of 5.04 in early 2022 to a peak of 6.04 by mid-2024, suggesting an acceleration in the rate at which supplier obligations are settled.
- Payables Turnover Dynamics
- A consistent upward trend in the payables turnover ratio is observed between April 2022 and June 2024. This shift indicates that the company transitioned from a turnover rate of approximately 5.0 to nearly 6.0, reflecting a more rapid conversion of accounts payable into expenditures. Following the peak in June 2024, the ratio entered a phase of stabilization, fluctuating within a narrow band between 5.45 and 5.78 through mid-2026.
- Trade Accounts Payable Trends
- A sustained contraction in trade accounts payable is evident. Balances decreased from a high of 2,419 million USD in July 2022 to a low of 1,596 million USD by September 2024. This reduction in the average liability balance is a primary driver behind the increased turnover ratio, as the company maintained lower outstanding obligations to suppliers relative to its cost of sales.
- Cost of Sales Correlation
- Cost of sales exhibited periodic volatility, peaking at 3,430 million USD in December 2022 before settling into a range between 2,230 million USD and 2,872 million USD for the remainder of the period. The increase in payables turnover occurred despite these fluctuations in cost of sales, suggesting that the change in ratio was driven more by strategic liability management and the reduction of accounts payable balances than by significant shifts in procurement volume.
Overall, the data reflects a transition toward a more aggressive payment cycle or a reduction in supplier credit utilization, resulting in a higher and more stable turnover rate from 2024 onward.
Working Capital Turnover
| Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Current assets | ||||||||||||||||||||||||
| Less: Current liabilities | ||||||||||||||||||||||||
| Working capital | ||||||||||||||||||||||||
| Sales | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Working capital turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q2 2026 Calculation
Working capital turnover
= (SalesQ2 2026
+ SalesQ1 2026
+ SalesQ4 2025
+ SalesQ3 2025)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of working capital turnover reveals a period of significant volatility in operational efficiency, characterized by a sharp decline in the first two years followed by a rapid correction and subsequent stabilization.
- Efficiency Erosion (April 2022 – September 2023)
- A consistent downward trend in working capital turnover is observed, with the ratio falling from 5.91 to a period low of 2.18. This decline was primarily driven by a substantial increase in working capital, which peaked at 11,838 million USD in September 2023, while sales figures remained relatively stagnant or experienced slight contractions. This suggests a period of decreased efficiency in utilizing short-term assets to generate revenue.
- Operational Correction and Peak Efficiency (December 2023 – December 2024)
- A dramatic reversal in the turnover trend occurred starting in late 2023. The turnover ratio surged from 4.22 to a peak of 8.85 by December 2024. This improvement was not driven by a proportional increase in sales, but rather by a significant reduction in working capital, which dropped to a low of 2,699 million USD. This indicates a strategic contraction of current assets or an increase in current liabilities, resulting in a lean operational structure and high capital velocity.
- Stabilization and Fluctuating Trends (March 2025 – June 2026)
- The final period is marked by increased fluctuation in the turnover ratio, ranging between 3.83 and 7.39. Working capital levels began to rise again, reaching 6,475 million USD in March 2026, which exerted downward pressure on the turnover ratio despite sales maintaining a general upward trajectory toward 6,265 million USD. The ratio ended the period at 4.76, suggesting a return to a more moderate level of working capital utilization compared to the extremes observed in 2023 and 2024.
Average Inventory Processing Period
| Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Inventory turnover | ||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||
| Average inventory processing period1 | ||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q2 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The relationship between inventory turnover and the average inventory processing period exhibits a consistent inverse correlation throughout the observed period. Fluctuations in turnover ratios directly correspond to changes in the number of days required to process inventory, reflecting shifts in operational efficiency and inventory management velocity.
- Inventory Turnover Trends
- The inventory turnover ratio maintained a general range between 3.20 and 4.15. A period of relative stability was observed throughout 2022 and 2023, with ratios fluctuating between 3.50 and 4.03. A peak in efficiency occurred on December 31, 2024, reaching a maximum ratio of 4.15. However, a significant decline is noted toward the end of the sequence, with the ratio dropping to its lowest point of 3.20 by June 26, 2026.
- Average Inventory Processing Period Analysis
- The processing period demonstrated cyclical volatility, beginning at 94 days in April 2022 and peaking at 104 days during the first and third quarters of 2023. A notable improvement in inventory throughput was recorded by December 31, 2024, where the processing period reached a minimum of 88 days. Following this trough, the period trended upward again, culminating in a sharp increase to 114 days by June 26, 2026, marking the longest duration of inventory holding in the analyzed timeframe.
- Operational Efficiency Observations
- Two distinct operational pivots are observable. The first occurred in late 2024, characterized by a synchronized peak in turnover and a minimum in processing days, suggesting a period of high liquidity and rapid inventory movement. The second pivot occurred in mid-2026, where the acceleration of the processing period to 114 days and the simultaneous drop in turnover to 3.20 indicate a substantial slowing of inventory circulation and potential accumulation of stock.
Average Receivable Collection Period
| Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Receivables turnover | ||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||
| Average receivable collection period1 | ||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q2 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of operating activity indicates a fluctuating but generally stable pattern in the management of accounts receivable over the observed period. A consistent inverse correlation exists between the receivables turnover ratio and the average receivable collection period, where increases in turnover correspond directly with reductions in the number of days required to collect payments.
- Collection Period Volatility
- The average receivable collection period fluctuated between a minimum of 51 days in June 2024 and a maximum of 60 days in December 2023. A cyclical pattern is observable, with collection times typically extending toward the end of the calendar year and compressing during the first or second quarters of the subsequent year.
- Receivables Turnover Efficiency
- The turnover ratio maintained a range between 6.09 and 7.15. Peak operational efficiency was recorded in June 2024, when the turnover ratio reached 7.15, coinciding with the lowest collection period of 51 days. This indicates a period of maximum velocity in converting receivables into cash.
- Long-term Trajectory and Recent Trends
- After a period of relative stability where the collection period remained constant at 54 days from March 2024 through June 2025, a gradual upward trend is noted. From September 2025 to June 2026, the collection period increased from 56 to 58 days, which aligns with a corresponding decline in the turnover ratio from 6.46 to 6.33, suggesting a slight slowdown in the collection process toward the end of the analyzed timeframe.
Operating Cycle
| Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Average inventory processing period | ||||||||||||||||||||||||
| Average receivable collection period | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Operating cycle1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Operating Cycle, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q2 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The analysis of the operating cycle indicates a period of relative stability punctuated by specific intervals of increased volatility, primarily driven by fluctuations in inventory management rather than credit collection efficiency.
- Average Inventory Processing Period
- Inventory processing times exhibited moderate volatility, generally oscillating between 88 and 114 days. A period of expansion was observed between March 2023 and September 2023, where the period peaked at 104 days. This was followed by a contraction reaching a low of 88 days by December 31, 2024. However, a significant upward trend emerged in the final period, culminating in a peak of 114 days on June 26, 2026, representing the highest inventory holding duration in the observed timeframe.
- Average Receivable Collection Period
- The collection of receivables remained remarkably consistent throughout the analyzed period. The duration stayed within a tight range of 51 to 60 days. While a slight peak occurred in December 2023 at 60 days, the metric quickly stabilized and maintained a narrow corridor between 51 and 58 days for the remainder of the timeline. This suggests a highly disciplined and predictable credit management process.
- Operating Cycle
- The total operating cycle, reflecting the combined time required to convert inventory into cash, ranged from a minimum of 142 days to a maximum of 172 days. Because the receivable collection period remained stable, the fluctuations in the total operating cycle were almost exclusively dictated by inventory processing efficiency. The cycle reached its most efficient point in December 2024 (142 days) and its least efficient point in June 2026 (172 days), coinciding with the observed spike in inventory holding times.
Overall, the operating cycle demonstrates a strong dependency on inventory throughput. The stability of the receivable collection period provides a consistent baseline, while the variance in the inventory processing period introduces the primary risk to short-term liquidity and operational efficiency.
Average Payables Payment Period
| Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Payables turnover | ||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||
| Average payables payment period1 | ||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q2 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity from April 2022 to June 2026 reveals a period of strategic adjustment in obligations management, characterized by an initial tightening of payment cycles followed by a phase of operational stabilization.
- Payables Turnover Analysis
- The payables turnover ratio demonstrated a general upward trend during the first half of the observed period. Starting from a low of 5.00 in July 2022, the ratio climbed to a peak of 6.04 by September 2024. This progression indicates an increase in the frequency with which supplier obligations were settled. From late 2024 through June 2026, the ratio entered a period of relative stability, fluctuating within a narrow range between 5.45 and 5.78.
- Average Payables Payment Period Trends
- The average payables payment period exhibited an inverse correlation with turnover, trending downward from a maximum of 73 days in July 2022 to a minimum of 60 days in September 2024. This reduction of 13 days suggests a shift toward more accelerated payment cycles. Following the September 2024 low, the payment period experienced a slight correction and subsequently stabilized, maintaining a consistent range between 63 and 67 days through the end of the analyzed period in June 2026.
- Operational Synthesis
- The convergence of increasing turnover and decreasing payment days through 2024 reflects a period of heightened liquidity utilization or a modification in supplier credit terms. The subsequent stabilization observed in 2025 and 2026 indicates that the organization reached an operational equilibrium, effectively maintaining a consistent payment cycle of approximately 64 days.
Cash Conversion Cycle
| Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Average inventory processing period | ||||||||||||||||||||||||
| Average receivable collection period | ||||||||||||||||||||||||
| Average payables payment period | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Cash conversion cycle1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q2 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The operational efficiency of the cash conversion cycle exhibits notable volatility over the analyzed period, characterized by periodic expansions and contractions. The overall trend indicates an increase in the time required to convert resource inputs into cash flows, culminating in a peak of 108 days by June 2026.
- Average Inventory Processing Period
- This metric serves as the primary driver of volatility within the cash conversion cycle. Values fluctuate between a low of 88 days in December 2024 and a high of 114 days in June 2026. A general upward trajectory is observed toward the end of the period, suggesting an increase in the time inventory remains on hand before being sold.
- Average Receivable Collection Period
- The collection of receivables remains relatively stable, maintaining a narrow range between 51 and 60 days. This consistency indicates a disciplined approach to credit management and steady payment behavior from customers throughout the observed timeframe.
- Average Payables Payment Period
- A slight downward trend is observed in the payment of payables, which decreased from peaks of 72-73 days in early 2022 to a range of 60-67 days in the subsequent years. This reduction in the payment window suggests a decrease in the amount of short-term financing obtained from suppliers.
- Cash Conversion Cycle
- The total cash conversion cycle mirrors the fluctuations of inventory processing. While the cycle reached a low of 75 days in April 2022 and 76 days in December 2024, it experienced significant expansion in mid-2023 and mid-2026. The increase to 108 days in the final quarter indicates a decline in short-term liquidity efficiency, driven predominantly by slower inventory turnover and a moderately compressed payables period.